Document is current

Article History

Received: 8 October 2018

Accepted: 20 December 2018

First Online: 4 March 2019

Ethics approval and consent to participate

: All animal procedures adhered to NIH Guidelines for the Care and Use of Laboratory Animals and were undertaken under authorization of the UCSF Institutional Animal Care and Use Committee in an AAALAC approved facility.

: Not applicable

: RJA, AM and OL are co-inventors of pending US patent 10167334  co-owned by UCSF and Xoma RJA and DS receive funding through a UCSF collaboration with Pfizer/CTI. DS owns stock in Pliant Therapeutics and has received more than $10,000 in consulting income from Pliant Therapeutics.. RJA has a Sponsored Research Agreement with Plexxikon Inc. DS has Sponsored Research Agreements with Pliant Therapeutics and Abbvie and is a co-inventor of 12 awarded patents and 6 pending patents owned or co-owned by the University of California, San Francisco. AB received funding through a collaboration with Bayer. AB is on the Advisory Boards of Mission Bio and InteRNA. MK owns stock in Pionyr Immunotherapeutics, and receives funding from Amgen, BMS and Abbvie to support the UCSF Immunoprofiler project. AM is currently an employee of Gilead and has direct equity ownership in XOMA Corporation and Gilead Sciences Inc. AM and OL were full time employees of XOMA Corporation during the period that this work was executed. AM and OL are coinventors on the following patents: Antibodies that bind Interleukin 2 and uses thereof – 2016 U.S. Provisional Utility Application M. Roell; A. Mirza; et al. Treatment of Cancer Using Inhibitors of TGFbeta and PD-1 – 2015. WIPO Patent Application WO/2016/161410A2 U.S. Prov. Utility Appl. No. 62/143,016; A. Mirza; O. Li; R. Akhurst. Antibodies targeting PTH1R to affect Humoral Hypercalemia of Malignancy and cancer – 2016 U.S. Provisional Utility Application A. Mirza; R. Levy; T. Takeuchi; D. Bedinger; and R. Hunt. Antibodies Specific for TGF-BETA – 2013 US 8,569,462; D. Bedinger; S. Khan; A. Mirza; A. Narasimha; T. Takeuchi. PRLR-Specific Antibody and Uses Thereof – 2008 WIPO Patent Application WO WO/2008/022295; D. Bedinger; J. Damiano; M. Luqman; L. Masat; A. Mirza; G. Nonet. Uses of Anti-CD40 Antibodies – 2008. WIPO Patent Application WO/2009/062054; M. Luqman; Y. Wang; S. Kantak; S. Hsu; A. Mirza. siRNA Libraries – 2004 WIPO Patent Application WO/2004/108897; C. Beraud; A. Mirza. OL is currently an employee of Five Prime Therapeutics, and has more than $10,000 in stock she is an inventor on three patents: including two listed above and Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia. DSM is an employee of Idorsia Pharmaceuticals Ltd. and holds equity in that company. MDT is an employee of, and holds ownership of equity in, Northern Biologics. MB is a coinventor on patent application PCT/US2015/052682, Modulation of stimulatory and non-stimulatory myeloid cells. MLB is currently an employee of Bristol-Myers Squibb.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.